IFRX · InflaRx N.V.

InflaRx reported its first quarter 2026 financial results, reflecting the impact of a strategic restructuring announced in January 2026. The company recorded a net loss of €5.6 million, a significant improvement from the €8.3 million loss in the same period last year, primarily due to a 45% reduction in total operating expenses to €7.5 million. Revenue remained at zero as the company discontinued GOHIBIC (vilobelimab) sales in the U.S. in December 2025. Research and development expenses fell 41% to €4.2 million, driven by lower third-party costs for vilobelimab and izicopan programs, as well as reduced personnel expenses. Sales and marketing expenses dropped 93% to €0.1 million, reflecting the wind-down of commercial activities. General and administrative expenses decreased 37% to €3.2 million. The net financial result was a gain of €1.6 million, down from €4.7 million a year ago, mainly due to lower fair value remeasurement gains on pre-funded warrants. Cash and marketable securities totaled €39.7 million as of March 31, 2026, which management believes will fund operations into 2027. The company also disclosed the upcoming resignation of Chief Medical Officer Dr. Camilla Chong, effective August 2026, with no disagreement cited. The restructuring focuses resources on izicopan, an oral C5aR inhibitor, with plans to initiate Phase 2b trials in hidradenitis suppurativa and explore other indications. Additional one-time restructuring costs of €0.6 million were incurred in Q1 2026.